Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again
This article was originally published in The Pink Sheet Daily
Antidepressant received two FDA “not approvable” letters when it was licensed to Organon.
You may also be interested in...
Do Negative Trials Count More Than Successful Ones?
Fabre-Kramer, FDA dispute over efficacy of the antidepressant gepirone heads to Psychopharmacologic Drugs Advisory Committee.
Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.
Fabre-Kramer/GSK Submit Gepirone ER For Major Depressive Disorder
Firms are seeking to secure FDA approval of the first-in-class 5HT1a agonist with new data.